SOTALOL HYDROCHLORIDE

Sotacor

Reviewed by Dr Patricia Clarkson, Dr Jon Skinner (October 1999), Brenda Hughes, Lejla Brkic, Robyn Wilkinson
January 1999
Administration updated August 2002
Dose and Pharmacology Newborn Drug Protocol Index Newborn Services Home Page

 

Management of  Sotolol Administration

Description

IV preparation

Oral preparation

Prescription

Administration

Slow IV Infusion

  1. Dilute immediately prior to use to 1mg/ml by adding to sodium chloride 0.9% or glucose 5% .
  2. Filter prior to administration through a 5 micron filter needle.
  3. Administer by slow IV infusion over 10 minutes using a syringe pump.
  4. Compatible with sodium chloride 0.9% or glucose 5%. Do not mix with other drugs or IV solutions
  5. Flush line with sodium chloride 0.9% before and after infusion of Sotalol.

Oral

  1. Follow instructions on bottle.
  2. Is preferable to administer before food 6. Be consistent when administering with or without food.
  3. Do not administer with calcium containing products.

Observation and Documentation

  1. Assess for signs of adverse reactions.
  2. Cardiorespiratory monitoring during acute usage. Report and record changes in heart rate and rhythm.
  3. Monitor blood pressure.
  4. Document vital signs.
  5. Document baby’s response to medication.

Storage

IV preparation

References

1 Saunders R, Knight J (eds). NE Compendium. Detailed prescribing information, Auckland, Adis Press 1992. p161-165.
2 Reynolds JEF Editor Martindale: The Extra Pharmacopoeia. (31st ed). Royal Pharmaceutical Society; 1996: London
3 Paediatric Pharmacopoeia, Royal Children’s Hospital Melbourne and Leicester Royal Infirmary Children’s Hospital . WB Saunders Co. Ltd; 1998: London
4 Clark WG, Brater DC, Johnson AR. Goth’s Medical Pharmacology. The CV Mosby Company 12th ed, 1988 p784.
5 Stockley I. Drug Interactions 4th ed. The Pharmaceutical Press; 1996: London
6 Paediatric Formulary. Guys, St Thomas’ and Lewisham Hospitals. 4th edition.
7 Hansten P. Horn J. Drug Interactions Analysis and Management. Applied Therapeutics Inc.; July 1998: Vancouver.